Abstract submission

On behalf of the Scientific Committee it is our pleasure to invite you to submit an abstract for the ANR meeting. The submission tool will open as of October 2021. Please note the submission deadline of 10 January 2022 in your agenda already! More information about the guidelines will follow soon.

Please keep an eye on this page, we will inform you when the abstract submission for ANR2022 is open.

Abstract Guidelines

General abstract submission guidelines

  1. Abstracts can only be submitted online via the abstract submission form. Abstracts sent by post or email will not be accepted.
  2. All mandatory fields must be filled out.
  3. Please choose one of the topics listed below* that best categorizes your abstract. This is important for the reviewing process.
  4. The maximum length of the abstract is 500 words.
  5. After the submission deadline it is not possible to make any changes.
  6. Please ensure correct spelling, grammar and scientific content, as abstracts will be reproduced exactly as submitted. Linguistic accuracy is your responsibility. No proof reading will be done.
  7. Individuals may be the first author of more than one abstract.
  8. The presenting author of the abstract must be registered for the meeting.
  9. Preferably use the following headings in your abstract:
    • Background / introduction
    • Aims
    • Methods / materials
    • Results
    • Summary / conclusion

Presentation preference

  • Oral Presentation
    will range from 10 to 15 minutes length. Presenting authors should use slides to accompany their presentation.
  • Rapid Fire Presentation
    Selected abstracts can be presented in Rapid Fire sessions of one slide during one minute.
  • Poster
    if your abstract is selected as an poster for the ANR2022 meeting we ask the first authors or a co-author to make themselves available during the breaks and lunch to answer questions.


Please select the topic which best fits with your abstract.

  1. Genes, genetic defects and dependencies driving neuroblastoma.
  2. Precision oncology (MYCN, RAS/MAPK, ALK, novel targets, combinatorial drugging, new strategies).
  3. Genetic heterogeneity in relation to resistance, progression and relapse.
  4. Phenotypic heterogeneity in relation to resistance, progression and relapse (plasticity, epigenetics).
  5. Normal development and the origin of neuroblastoma.
  6. Neuroblastoma biology (metabolism, DNA repair, genomic instability, etc.).
  7. Preclinical immunology studies and micro-environment.
  8. Early clinical trials  – targeted and other novel therapies.
  9. Immune therapy (clinical, CART, GD2).
  10. Relapse treatment (SIOPEN, NANT/COG).
  11. New developments in surgery and radiotherapy.
  12. Liquid biopsies, theranostics and imaging.
  13. Treatment of neuroblastoma in low and middle income countries.
  14. Miscellaneous.